Somavert (Pegvisomant) - Current Clinical Trials

Somavert Related Clinical Trials

Acute Application of Pegvisomant and Octreotide in Acromegaly [Completed]

Pegvisomant And Sandostatin LAR Combination Study [Completed]

Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients [Completed]

Canadian Pegvisomant Compassionate Study In Acromegalic Patients [Completed]

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [Active, not recruiting]

Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan [Active, not recruiting]

Effect of Pegvisomant on GH/IGF-I Relationship in GHD [Terminated]

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome [Completed]

Co-Treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-Responsive Acromegalic Patients [Recruiting]

Long Term Study With B2036-PEG [Completed]

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant [Recruiting]

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly [Completed]

Growth Hormone Signaling in Vivo in Humans [Completed]

Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content [Recruiting]